Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNK-651
- Development stage
- Unknown
- Lead developer
- Denka
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
DNK-651 is a virus-like particle (VLP) vaccine candidate developed by Denka (formerly Denka Seiken) for the prevention of norovirus infection. Noroviruses are a leading cause of acute gastroenteritis worldwide, and currently, no licensed vaccines are available. DNK-651 is designed to elicit a protective immune response against norovirus by mimicking the viral structure without containing genetic material. It is being evaluated in early-stage clinical trials in Japan, specifically investigating safety and immunogenicity via intradermal and subcutaneous administration routes in both young and elderly healthy adults.
02
Targets
Norovirus VP1TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on DNK-651.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNK-651.